Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Triamcinolone Acetonide
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Agreement
Harrow Executes Five-Year Strategic Supply and Development Agreement for TRIESENCE®
Details : The agreement aims for supply and development of Triesence (triamcinolone acetonide injectable suspension), a preservative-free synthetic corticosteroid.
Product Name : Triesence
Product Type : Hormone
Upfront Cash : Undisclosed
March 11, 2025
Lead Product(s) : Triamcinolone Acetonide
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Cyclosporine
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Harrow Announces Market Access Wins for VEVYE®
Details : Vevye is an approved cyclosporine ophthalmic solution, designed to address unmet needs, providing patients with a fast acting and well tolerable dry eye drug therapy.
Product Name : Vevye
Product Type : Peptide
Upfront Cash : Inapplicable
December 11, 2024
Lead Product(s) : Cyclosporine
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cyclosporine
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Harrow Announces 52-Week Data from VEVYE® ESSENCE-2 Open-Label Extension Study
Details : Vevye is an approved cyclosporine ophthalmic solution, designed to address unmet needs, providing patients with a fast acting and well tolerable dry eye drug therapy.
Product Name : Vevye
Product Type : Peptide
Upfront Cash : Inapplicable
May 06, 2024
Lead Product(s) : Cyclosporine
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Triamcinolone Acetonide
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Triesence is an injectable suspension containing triamcinolone acetonide, a synthetic corticosteroid, which is indicated for the treatment of sympathetic ophthalmia, temporal arteritis & uveitis.
Product Name : Triesence
Product Type : Hormone
Upfront Cash : Inapplicable
March 10, 2024
Lead Product(s) : Triamcinolone Acetonide
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cyclosporine
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Apotex Inc
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Harrow Licenses Canadian Rights to Apotex for Five Ophthalmic Products
Details : Through a licensing agreement, Apotex will market Verkazia (cyclosporine) ophthalmic emulsion, a calcineurin inhibitor indicated for treating vernal keratoconjunctivitis in children and adults.
Product Name : Vevye
Product Type : Peptide
Upfront Cash : Undisclosed
February 15, 2024
Lead Product(s) : Cyclosporine
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Apotex Inc
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Moxifloxacin Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Harrow Launches VIGAMOX in the U.S.
Details : VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) is a fluoroquinolone antibiotic eye drop approved for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms.
Product Name : Vigamox
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 31, 2023
Lead Product(s) : Moxifloxacin Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nepafenac
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : $130.0 million
Deal Type : Acquisition
Details : Ilevro (nepafenac) is a non-steroidal anti-inflammatory drug (NSAID). It stops the body from making chemicals that cause inflammation, which helps lessen pain and swelling in the eye due to surgery.
Product Name : Ilevro
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 23, 2023
Lead Product(s) : Nepafenac
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : $130.0 million
Deal Type : Acquisition
Lead Product(s) : Midazolam,Ketamine Hydrochloride,Ondansetron
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Approved FDF
Sponsor : iOR Partners
Deal Size : Undisclosed
Deal Type : Agreement
Harrow and iOR Partners Expand National Product Supply Agreement
Details : The MKO melt (midazolam) is being marketed as an anesthetic medication for cataract surgery that has the advantage that it eliminates the need for an IV in 85% of patients although that number was established anecdotally.
Product Name : MKO Melt
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
November 30, 2022
Lead Product(s) : Midazolam,Ketamine Hydrochloride,Ondansetron
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Approved FDF
Sponsor : iOR Partners
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Apomorphine Hydrochloride
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Harrow Health Announces Launch of IOPIDINE® 1% and MAXITROL® in the United States
Details : IOPIDINE 1% Ophthalmic Solution contains apraclonidine hydrochloride, an alpha-adrenergic agonist, in a sterile isotonic solution for topical application to the eye.
Product Name : Iopidine
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 24, 2022
Lead Product(s) : Apomorphine Hydrochloride
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable